(0.14%) 5 138.75 points
(0.09%) 38 474 points
(0.22%) 17 886 points
(-0.29%) $83.61
(1.61%) $1.954
(0.13%) $2 350.30
(0.62%) $27.71
(1.53%) $936.20
(-0.18%) $0.933
(-0.31%) $10.99
(-0.31%) $0.798
(1.15%) $92.93
0.81% KRW 6 200.00
Live Chart Being Loaded With Signals
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments...
Stats | |
---|---|
Šios dienos apimtis | 97 884.00 |
Vidutinė apimtis | 689 294 |
Rinkos kapitalizacija | 408.25B |
EPS | KRW0 ( 2024-04-22 ) |
Kita pelno data | ( KRW0 ) 2024-05-13 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW7.24 (0.12%) |
Tūris Koreliacija
Bukwang Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bukwang Pharmaceutical Koreliacija - Valiuta/Žaliavos
Bukwang Pharmaceutical Finansinės ataskaitos
Annual | 2023 |
Pajamos: | KRW125.93B |
Bruto pelnas: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2023 |
Pajamos: | KRW125.93B |
Bruto pelnas: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2022 |
Pajamos: | KRW190.91B |
Bruto pelnas: | KRW79.43B (41.61 %) |
EPS: | KRW-62.07 |
FY | 2021 |
Pajamos: | KRW182.49B |
Bruto pelnas: | KRW75.76B (41.51 %) |
EPS: | KRW-8.74 |
Financial Reports:
No articles found.
Bukwang Pharmaceutical
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.